Based in the United Kingdom, Vigeo is a startup.
Vigeo is developing a first-in-class drug discovery pipeline that reprograms the tumor microenvironment to enhance immune response against solid tumors, with lead compounds targeting thrombospondin expression to inhibit immune checkpoint signals such as CD36 and CD47.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.